Acute Lymphoblastic Leukemia Panel
clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
IV cetirizine Submitted by TerSera Therapeutics on 11/09/2021
Glucarpidase/use of MTXPK.org Submitted by BTG International on 05/26/2022
Remote Continuous Temperature Monitoring Submitted by Blue Spark Technologies on 09/20/2022
ponatinib + blinatumomab Submitted by Takeda Oncology on 09/30/2022
Inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/03/2022
Continuous temperature monitoring Submitted by Blue Spark Technologies on 09/18/2023
inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/30/2023
inotuzumab ozogamicin Submitted by Pfizer Inc. on 10/30/2023
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 05/01/2020
CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020
Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020
Venetoclax Submitted by AbbVie, Inc. and Genentech, Inc. on 01/25/2021
Daunorubicin and cytarabine Submitted by Jazz Pharmaceuticals Inc. on 03/21/2023
APL Differentiation Syndrome Submitted by Blue Spark Technologies on 03/23/2023
Adolescent and Young Adult Oncology Panel
Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020
Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020
Intravenous patient controlled analgesia Submitted by Fujian Cancer Hospital on 06/19/2022
IV cetirizine Submitted by TerSera Therapeutics on 06/28/2023
Polatuzumab Vedotin Submitted by Genentech, Inc. on 12/17/2019
2 Gy x 2 fractions Submitted by Oncology Analytics, Inc. on 02/08/2020
Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020
NGS clarification Submitted by Adaptive Biotechnologies on 09/01/2020
Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 02/08/2021
Loncastuximab tesirine‐lpyl Submitted by ADC Therapeutics on 04/23/2021
Tafasitamab-cxix Submitted by Dr. Wei Jiang, PhD and Dr. Michael Cuozzo, PharmD on 09/01/2021
polatuzumab vedotin-piiq Submitted by Genentech, Inc. on 12/15/2021
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 04/05/2022
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 06/01/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 06/13/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 06/21/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 06/24/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 08/04/2022
acalabrutinib + acid-reducing agents Submitted by AstraZeneca on 09/01/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 12/19/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/19/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 01/05/2023
Pirtobrutinib Submitted by Eli Lilly and Company on 01/27/2023
Epcoritamab-bysp Submitted by AbbVie, Inc. and Genmab US, Inc on 05/22/2023
Acalabrutinib + rituximab Submitted by AstraZeneca on 07/11/2023
Castleman Disease Submitted by Castleman Disease Collaborative Network (CDCN) on 08/15/2023
Enfortumab vedotin Submitted by Seattle Genetics, Inc. on 12/06/2019
Avelumab Submitted by EMD Serono and Pfizer Inc. on 06/30/2020
Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020
Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020
Avelumab Submitted by EMD Serono and Pfizer Inc. on 09/18/2020
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/15/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2021
Enfortumab vedotin-ejfv Submitted by Seagen Inc on 07/13/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/20/2021
Nadofaragene firadenovec Submitted by Ferring Pharmaceuticals on 12/16/2022
Pembrolizumab Footnote Submitted by Merck & Co., Inc. on 02/17/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/02/2023
Cxbladder Triage Submitted by Pacific Edge Diagnostics USA, Ltd. on 07/11/2023
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 07/19/2023
Pembrolizumab + enfortumab vedotin-ejfv Submitted by Pfizer and Astellas Pharma Inc. on 12/15/2023
Pembrolizumab + enfortumab vedotin-ejfv Submitted by Merck & Co., Inc. on 12/18/2023
Enfortumab vedotin-ejfv Submitted by Pfizer and Astellas Pharma Inc. on 03/06/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/30/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/15/2021
Comprehensive genomic profiling (CGP) Submitted by Illumina Inc. on 04/27/2021
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/20/2023
OncoKB Submitted by Memorial Sloan Kettering Cancer Center on 05/11/2023
Glucarpidase Submitted by SERB Pharmaceuticals and BTG International on 01/04/2024
Abemaciclib Submitted by Eli Lilly and Company on 10/29/2019
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 01/02/2020
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 01/27/2020
Estrogen receptor alpha-36 testing Submitted by Christina Rosati on 02/25/2020
Neratinib + capecitabine Submitted by Puma Biotechnology on 02/27/2020
docetaxel_carboplatin_trastuzumab Submitted by Guangdong Academy of Medical Sciences on 03/22/2020
Sacituzumab govitecan-hziy Submitted by Immunomedics, Inc. on 04/22/2020
Alpelisib + fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 05/12/2020
TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020
Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 07/20/2020
21-Gene RT-PCR assay Submitted by Exact Sciences Inc. on 07/28/2020
PET/CT Submitted by Society of Interventional Oncology on 07/30/2020
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 08/01/2020
Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech, Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
NGS assay Submitted by Foundation Medicine, Inc. on 08/06/2020
TMB testing Submitted by Foundation Medicine, Inc. on 09/15/2020
Atezolizumab + albumin-bound paclitaxel Submitted by Genentech, Inc. on 12/02/2020
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 01/29/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/08/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/26/2021
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 05/21/2021
Comprehensive Genomic Profiling Submitted by Illumina Inc. on 05/26/2021
APBI Dosing Submitted by Schwartzberg Center for Minimally Invasive Breast Surgery on 07/13/2021
Vaginal pH modulator Submitted by Evofem Biosciences, Inc. on 07/13/2021
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/15/2021
12-Gene (EndoPredict) Assay Submitted by Myriad Genetic Laboratories, Inc. on 07/20/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/02/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/07/2021
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 09/21/2021
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 09/29/2021
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 10/11/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/14/2021
Abemaciclib Submitted by Agilent Technologies, Inc. on 10/20/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/28/2021
Docetaxel plus carboplatin Submitted by Guangdong Academy of Medical Sciences on 11/14/2021
bioimpedance spectroscopy Submitted by Cleveland Clinic on 11/20/2021
bioimpedance spectroscopy Submitted by Vanderbilt University School of Nursing on 02/09/2022
ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/06/2022
ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 06/10/2022
neratinib_fulvestrant_trastuzumab Submitted by Puma Biotechnology on 07/18/2022
SBRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
IMRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
Perjeta and Herceptin Submitted by Genentech, Inc. on 07/29/2022
fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 08/08/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/12/2022
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 12/20/2022
Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 12/20/2022
Elacestrant Submitted by Stemline Therapeutics, Inc. on 01/30/2023
Abemaciclib Submitted by Eli Lilly and Company on 03/10/2023
RCB score Submitted by American Joint Committee on Cancer/American College of Surgeons on 07/06/2023
Leuprolide Submitted by Compass Oncology, The US Oncology Network on 07/18/2023
DPYD testing Submitted by Advocates for Universal DPD/DPYD Testing (AUDT) on 07/28/2023
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/31/2023
Locoregional therapies Submitted by Society of Interventional Oncology on 07/31/2023
ipilimimab + nivolumab Submitted by Sylvia Adams and Razelle Kurzrock on 10/16/2023
Capivasertib with Fulvestrant Submitted by Foundation Medicine Inc on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
Capivasertib + fulvestrant Submitted by Astrazeneca on 11/16/2023
PIK3CA/AKT1/PTEN Submitted by Foundation Medicine Inc on 12/15/2023
PIK3CA or AKT1/PTEN Submitted by Foundation Medicine Inc on 12/15/2023
Sacituzumab govitecan-hziy Submitted by Evicore on 01/05/2024
Sacituzumab govitecan-hziy Submitted by Evicore on 01/05/2024
abemaciclib in combination with endocrine therapy Submitted by Eli Lilly and Company on 01/11/2024
abemaciclib in combination with endocrine therapy Submitted by Eli Lilly and Company on 01/11/2024
Breast Cancer Risk Reduction Panel
riskScore™ Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2020
geneType model Submitted by Phenogen Sciences, Inc on 03/13/2023
Polygenic Risk Score Submitted by Myriad Genetic Laboratories, Inc. on 04/21/2023
Polygenic Risk Scores (PRS) Submitted by Myriad Genetics on 04/22/2024
Rationale: Polygenic Risk Scores (PRS) Submitted by Myriad Genetics on 04/22/2024
Breast Cancer Screening and Diagnosis Panel
Cancer in People with HIV/Kaposi Sarcoma Panel
Cancer-Associated Venous Thromboembolic Disease Panel
Central Nervous System Cancers Panel
Aminolevulinic acid hydrochloride Submitted by NX Development Corp on 06/02/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/23/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 12/11/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/16/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 09/22/2021
Nivolumab in combination with ipilimumab Submitted by Bristol-Myers Squibb Company on 06/06/2023
Intrathecal nivolumab Submitted by The University of Texas MD Anderson Cancer Center on 06/25/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 06/28/2023
Add a section for brachytherapy implant Submitted by GT Medical Technologies, Inc. on 08/03/2023
Olutasidenib Submitted by Rigel Pharmaceuticals, Inc. on 09/08/2023
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 07/03/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 08/06/2024
Vorasidenib Submitted by Servier Pharmaceuticals on 08/06/2024
Cervical/Uterine Cancers Panel
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/17/2019
Nivolumab for Vulvar Cancer Submitted by Bristol-Myers Squibb Company on 10/17/2019
Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab dosing for Vulvar Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020
Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020
Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Oral selixinor for Endometrial Carcinoma Submitted by Karyopharm Therapeutics on 01/21/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 02/11/2021
Lenvatinib and pembrolilzumab for Uterine Neoplasms Submitted by Eisai Inc. on 02/11/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 03/19/2021
Pembrolizumab and Lenvatinib for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2021
Dostarlimab-gxly (Uterine Neoplasms) Submitted by GlaxoSmithKline on 04/22/2021
Dostarlimab-gxly for Uterine Neoplasms Submitted by GlaxoSmithKline on 04/28/2021
Cabozantinib for Uterine Neoplasms Submitted by Exelixis Inc. on 05/05/2021
TMB Testing for Cervical Cancer Submitted by Illumina Inc. on 05/13/2021
Comprehensive genomic profiling for Uterine Neoplasms Submitted by Illumina Inc. on 05/13/2021
Tisotumab vedotin-tftv for Cervical Cancer Submitted by Seagen Inc on 05/14/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 06/17/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 07/22/2021
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 09/20/2021
Dostarlimab-gxly (Uterine) Submitted by GlaxoSmithKline on 10/18/2021
Lenvatinib in combination with pembrolizumab (Uterine) Submitted by Eisai Inc. on 11/03/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme on 02/10/2022
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 03/23/2022
Pembrolizumab in combination with lenvatinib (Uterine) Submitted by Merck & Co., Inc. on 03/24/2022
Nivolumab with Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab with Ipilimumab (Uterine) Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Guideline reference Submitted by American Society for Radiation Oncology on 04/26/2022
Comprehensive Genomic Profiling (Uterine) Submitted by Foundation Medicine, Inc. on 05/19/2022
Tisotumab vedotin in combination with pembrolizumab Submitted by Seagen Inc on 05/27/2022
Dostarlimab-glxy (Uterine) Submitted by GlaxoSmithKline on 06/08/2022
Selpercatinib for RET fusion-positive tumors Submitted by Eli Lilly and Company on 09/21/2022
Albumin-bound sirolimus (Uterine Sarcoma) Submitted by Aadi Bioscience on 11/10/2022
Dostarlimab-gxly for dMMR/MSI-H tumors (Uterine) Submitted by GlaxoSmithKline on 03/27/2023
Dostarlimab-gxly/carboplatin/paclitaxel (Uterine) Submitted by GlaxoSmithKline on 03/27/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 04/18/2023
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 05/19/2023
Footnote (Uterine Sarcoma) Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
Sacituzumab govitecan-hziy (Endometrial) Submitted by Gilead Sciences, Inc. on 06/21/2023
Adagrasib for KRAS G12C (Uterine Neoplasms) Submitted by Mirati Therapeutics, Inc. on 08/11/2023
Albumin-bound sirolimus (Uterine Sarcoma) Submitted by Aadi Bioscience on 09/12/2023
Carboplatin + Paclitaxel + Durvalumab Submitted by AstraZeneca on 03/26/2024
Carboplatin/Paclitaxel/Durvalumab Submitted by AstraZeneca on 03/26/2024
Chronic Myeloid Leukemia Panel
CLL/SLL/Hairy Cell Leukemia Panel
Moxetumomab pasudotox-tdfk Submitted by Innate Pharma, Inc. on 05/08/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 05/12/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 06/02/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 09/11/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 09/30/2020
Ibrutinib Submitted by Janssen Biotech, Inc. and Pharmacyclics, LLC on 12/06/2020
Venetoclax Submitted by AbbVie, Inc. and Genentech, Inc. on 01/11/2021
Vemurafenib + rituximab Submitted by Genentech, Inc. on 05/21/2021
Ibrutinib Submitted by AbbVie, Inc., Janssen Biotech, Inc. and Pharmacyclics, LLC on 05/19/2022
MRD testing Submitted by Adaptive Biotechnologies on 05/27/2022
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. and Genentech, Inc. on 08/30/2022
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/19/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/20/2022
Ibrutinib Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 12/20/2022
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Pharmacyclics, LLC on 05/29/2023
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 01/24/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/09/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/09/2024
Ibrutinib Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/24/2024
Ibrutinib + Venetoclax Submitted by AbbVie, Inc. and Janssen Biotech, Inc. on 05/24/2024
Lisocabtagene Maraleucel Submitted by Bristol-Myers Squibb Company on 06/03/2024
Colon/Rectal/Anal Cancers Panel
Comprehensive genomic profiling (CGP) Submitted by Guardant Health on 01/30/2020
Pembrolizumab for Anal Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/01/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/09/2020
Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020
Next-generation sequencing (NGS) Submitted by Guardant Health on 07/20/2020
Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 10/04/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 02/16/2021
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
ctDNA for Colon Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
ctDNA for Rectal Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
Encorafenib + Cetuximab Submitted by Pfizer Inc. on 07/01/2021
CGP for Colon Cancer Submitted by Guardant Health on 07/02/2021
CGP for Rectal Cancer Submitted by Guardant Health on 07/02/2021
Dostarlimab-gxly for Colon Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Small Bowel Adenocarcinoma Submitted by GlaxoSmithKline on 08/17/2021
Sotorasib for Colon/Rectal Cancers Submitted by Amgen Inc. on 12/15/2021
Sotorasib for Colon/Rectal Cancers Submitted by Amgen Inc. on 12/15/2021
Nivolumab + ipilimumab for Anal Carcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Colon Cancer Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Rectal Cancer Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Guideline for Rectal Cancer Submitted by American Society for Radiation Oncology on 04/26/2022
Surveillance for Anal Carcinoma Submitted by Patient on 05/09/2022
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 05/12/2022
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 05/12/2022
Metastasis to peritoneum only for Rectal Cancer Submitted by NSCB Cancer Hospital on 05/31/2022
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 06/24/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Colorectal Cancer Alliance on 07/08/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Fight Colorectal Cancer on 07/18/2022
ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/19/2022
ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/19/2022
ctDNA testing for Colon/Rectal Cancers Submitted by COLONTOWN on 07/21/2022
ctDNA testing for Colon/Rectal Cancers Submitted by Colon Cancer Coalition on 07/25/2022
FOLFOX + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 07/25/2022
Trifluridine/tipiracil plus bevacizumab Submitted by Taiho Oncology, Inc. on 07/27/2022
DPYD variant testing for Anal Carcinoma Submitted by Invitae on 08/01/2022
DPYD variant testing for Colon/Rectal Cancers Submitted by Invitae on 08/01/2022
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 08/02/2022
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 08/02/2022
Sotorasib + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 09/15/2022
Selpercatinib for Colon/Rectal Cancer Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib for Small Bowel Adenocarcinoma Submitted by Eli Lilly and Company on 09/21/2022
Tucatinib + trastuzumab for Rectal Cancer Submitted by Seagen Inc on 01/20/2023
Tucatinib + trastuzumab for Colon Cancer Submitted by Seagen Inc on 01/20/2023
Retifanlimab-dlwr for Anal Carcinoma Submitted by Incyte Corporation on 04/18/2023
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 05/03/2023
Fam-trastuzumab deruxtecan-nxki for Rectal Cancer Submitted by Daiichi-Sankyo, Inc. on 06/21/2023
Fam-trastuzumab deruxtecan-nxki for Colon Cancer Submitted by Daiichi-Sankyo, Inc. on 06/21/2023
FOLFOX + panitumumab for Colon/Rectal Cancers Submitted by Amgen Inc. on 06/22/2023
ctDNA for Rectal Cancer Submitted by Natera, Inc. on 06/22/2023
ctDNA for Colon Cancer Submitted by Natera, Inc. on 06/22/2023
Ziv-aflibercept for Colon/Rectal Cancers Submitted by Sanofi on 06/30/2023
Ziv-aflibercept for Colon/Rectal Cancers Submitted by Sanofi on 06/30/2023
Quantitative multiparametric MRI for Colon Cancer Submitted by Perspectum Ltd on 07/17/2023
Tucatinib plus trastuzumab for Colon Cancer Submitted by Seagen Inc on 07/27/2023
Tucatinib plus trastuzumab for Rectal Cancer Submitted by Seagen Inc on 07/27/2023
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 07/27/2023
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 07/27/2023
CDx for Colon Cancer Submitted by Guardant Health on 07/29/2023
CDx for Rectal Cancer Submitted by Guardant Health on 07/31/2023
Avelumab for Colon/Rectal Cancers Submitted by EMD Serono on 08/21/2023
Colorectal Cancer Screening Panel
FIT-DNA-based testing Submitted by Exact Sciences Inc. on 10/13/2020
mt-s DNA Test Submitted by on 10/06/2021
Esophageal/Gastric Cancers Panel
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 03/12/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Esophageal and Esophagogastric Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020
Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020
Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 05/18/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 06/18/2021
Trifluridine and tipiracil (Esophageal and Gastric) Submitted by Taiho Oncology, Inc. on 07/26/2021
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/08/2021
Comprehensive genomic profiling (Esophageal) Submitted by Foundation Medicine, Inc. on 08/10/2021
Comprehensive genomic profiling (Gastric) Submitted by Foundation Medicine, Inc. on 08/10/2021
Methylation-based blood test (Esophageal and Gastric) Submitted by Grail, Inc. on 08/22/2021
Pembrolizumab in combination with chemotherapy Submitted by Merck & Co., Inc. on 08/30/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 09/24/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 01/26/2022
Tislelizumab (Esophageal) Submitted by Novartis Pharmaceuticals Corporation on 05/26/2022
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/31/2022
Spatialomics risk stratification (Esophageal) Submitted by Castle Biosciences on 07/26/2022
Selpercatinib (Esophageal) Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib (Gastric) Submitted by Eli Lilly and Company on 09/21/2022
Nivolumab plus ipilimumab (Esophageal) Submitted by Bristol-Myers Squibb Company on 01/20/2023
Pembrolizumab (Esophageal) Submitted by Merck & Co., Inc. on 03/30/2023
PET-directed therapy (Esophageal) Submitted by Icahn School of Medicine at Mount Sinai on 06/25/2023
Circulating tumor DNA (Esophageal) Submitted by Natera, Inc. on 07/28/2023
Circulating tumor DNA (Gastric) Submitted by Natera, Inc. on 07/28/2023
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 03/30/2024
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel
High Penetrance Genes Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2020
Polygenic Risk Scores Submitted by Myriad Genetic Laboratories, Inc. on 03/16/2021
Polygenic Risk Scores Submitted by Bright Pink on 03/17/2021
Polygenic risk scores Submitted by Myriad Genetic Laboratories, Inc. on 03/28/2022
Polygenic risk scores Submitted by Myriad Genetic Laboratories, Inc. on 03/07/2023
Genetic/Familial High-Risk Assessment: Colorectal Panel
Lynch Syndrome Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
CRC Modifications Submitted by Myriad Genetic Laboratories, Inc. on 11/05/2020
Microsatellite Instability assays Submitted by Promega Corporation on 10/27/2021
Universal genetic testing Submitted by Invitae on 11/05/2023
Universal genetic testing Submitted by Invitae on 11/06/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Multi-cancer early detection (MCED) testing Submitted by GRAIL on 11/08/2023
Trastuzumab/pertuzumab Submitted by Genentech, Inc. on 02/18/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 05/28/2020
NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020
Next generation sequencing Submitted by Kura Oncology, Inc. on 04/29/2021
Tumor mutational burden Submitted by Illumina Inc. on 05/13/2021
Circulating cell-free DNA Submitted by Grail, Inc. on 05/28/2021
Lymphedema Submitted by Vanderbilt University School of Nursing on 05/28/2021
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/11/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/20/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Plasma-Based Comprehensive Genomic Profiling (CGP) Submitted by Guardant Health on 06/01/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Pembrolizumab, carboplatin, and paclitaxel Submitted by Merck & Co., Inc. on 11/08/2022
Transoral Surgery Submitted by ECOG-ACRIN Cancer Research Group on 11/14/2022
Nivolumab plus ipilimumab Submitted by Bristol-Myers Squibb Company on 03/17/2023
Toripalimab-tpzi Submitted by Coherus BioSciences on 10/30/2023
Hematopoietic Cell Transplantation Panel
Defibrotide sodium Submitted by Jazz Pharmaceuticals Inc. on 10/22/2020
Belumosudil Submitted by Kadmon Corporation LLC on 07/21/2021
Abatacept Submitted by Bristol-Myers Squibb Company on 12/14/2021
Fostamatinib Submitted by Rigel Pharmaceuticals, Inc. on 03/10/2023
Continuous temperature monitoring Submitted by Blue Spark Technologies on 09/12/2023
Motixafortide + filgrastim (G-CSF) Submitted by BioLineRx on 09/22/2023
Abatacept Submitted by Bristol-Myers Squibb Company on 10/05/2023
Hematopoietic Growth Factors Panel
Eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/31/2020
Pegfilgrastim Submitted by Coherus BioSciences on 09/17/2020
Ferric Derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 09/21/2020
ferric derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 03/09/2021
plinabulin_pegfilgrastin Submitted by BeyondSpring Pharmaceuticals, Inc. on 09/15/2021
Pegfilgrastim Submitted by on 09/28/2021
ferric carboxymaltose Submitted by American Regent on 03/24/2022
eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/03/2022
Ferric derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 12/20/2022
Noninvasive continuous temperature monitoring Submitted by Blue Spark Technologies on 05/03/2023
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 11/23/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 03/11/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/13/2020
Molecular testing Submitted by Foundation Medicine, Inc. on 05/14/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020
Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/06/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/26/2021
Trastuzumab + pertuzumab Submitted by Genentech, Inc. on 08/11/2021
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 09/08/2021
Radioembolization Submitted by Society of Interventional Oncology on 09/08/2021
Liposomal irinotecan Submitted by Ipsen Biopharmaceuticals, Inc. on 11/24/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/16/2021
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 01/21/2022
Pembrolizumab monotherapy Submitted by Merck & Co., Inc. on 01/21/2022
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. and Sanofi on 02/17/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 04/06/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 06/23/2022
T-DXd Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/05/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 08/22/2022
Cabozantinib + Atezolizumab Submitted by Exelixis Inc. on 09/12/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/14/2022
ASTRO Review Submitted by American Society for Radiation Oncology on 09/19/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Thermal Ablation Submitted by Society of Interventional Oncology on 09/30/2022
Oncoguard Submitted by Community Liver Alliance on 10/20/2022
Tremelimumab-actl plus durvalumab Submitted by AstraZeneca on 10/24/2022
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 11/15/2022
Adagrasib Submitted by Mirati Therapeutics, Inc. on 04/26/2023
T-DXd Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/06/2023
Tucatinib plus trastuzumab Submitted by Seagen Inc on 09/19/2023
Cabozantinib tablets Submitted by Exelixis Inc. on 09/21/2023
Atezolizumab + Bevacizumab Submitted by Genentech on 11/01/2023
Camrelizumab + Rivoceranib Submitted by Elevar Therapeutics on 04/02/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Thermal Ablation Submitted by Society of Interventional Oncology on 03/02/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/13/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 09/24/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/07/2020
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 01/25/2021
Nivolumab + Cabozantinib Submitted by Exelixis Inc. on 01/25/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 02/11/2021
Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021
Lenvatinib + Everolimus Submitted by Eisai Inc. on 02/13/2021
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 03/04/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/05/2021
Management of T1a renal masses Submitted by Society of Interventional Oncology on 03/31/2021
Tivozanib + Nivolumab Submitted by AVEO Oncology on 04/16/2021
Cabozantinib + Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 09/02/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/14/2021
Thermal Ablation Submitted by Society of Interventional Oncology on 02/11/2022
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/21/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/17/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/15/2022
Thermal Ablation Submitted by Society of Interventional Oncology on 03/08/2023
Thermal Ablation Submitted by Society of Interventional Radiology on 03/21/2023
Pembrolizumab + lenvatinib Submitted by Merck & Co., Inc. on 02/07/2024
Toripalimab/Axitinib Submitted by Coherus Biosciences on 03/26/2024
Toripalimab/Axitinib Submitted by Coherus Biosciences on 03/26/2024
Management of Immunotherapy-Related Toxicity Panel
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 11/07/2019
Sargramostim Submitted by Partner Therapeutics on 06/17/2021
Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 07/08/2021
nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 06/10/2022
Intravenous (IV) cetirizine hydrochloride Submitted by TerSera Therapeutics on 06/30/2022
IV Cetirizine Submitted by TerSera Therapeutics on 05/16/2023
Continuous temperature monitoring Submitted by Blue Spark Technologies on 05/18/2023
Pembrolizumab dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Pembrolizumab dosing Submitted by Merck & Co., Inc. on 04/29/2020
Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020
Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020
Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020
DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020
PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020
Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020
PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020
Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020
Liquid biopsy-based DNA testing Submitted by Illumina Inc. on 05/28/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
Pembrolizumab and Lenvatinib Submitted by Merck & Co., Inc. on 06/07/2021
Adjuvant RT Submitted by American Society for Radiation Oncology on 06/11/2021
Pigmented lesion assay Submitted by DermTech, Inc. on 06/11/2021
Ipilimumab and sargramostim Submitted by Partner Therapeutics on 06/11/2021
Genomic patch testing Submitted by Georgetown University on 06/13/2021
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 12/02/2021
Pembrolizumab and lenvatinib (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 01/25/2022
Nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 03/18/2022
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 06/10/2022
Gene expression profiling (Melanoma: Cutaneous) Submitted by Castle Biosciences on 06/12/2022
Cutaneous Melanoma Submitted by Guardant Health on 06/15/2022
GEP Testing for Uveal Melanoma Submitted by Castle Biosciences on 09/29/2022
Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 10/11/2022
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 05/02/2023
Neoadjuvant pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 05/04/2023
GEP test (Cutaneous Melanoma) Submitted by Castle Biosciences on 06/16/2023
Tebentafusp-tebn and durvalumab (Cutaneous Melanoma) Submitted by Immunocore on 06/16/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/16/2023
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Lifileucel Submitted by Iovance and Iovance Biotherapeutics, Inc. on 02/21/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024
Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 12/20/2019
Lenalidomide Submitted by Bristol-Myers Squibb Company on 01/16/2020
Dexamethasone Submitted by Acrotech Biopharma LLC on 03/18/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 05/12/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 06/16/2020
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020
Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 02/01/2021
Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021
MRD assessment Submitted by Adaptive Biotechnologies on 03/25/2021
Idecabtagene Vicleucel Submitted by Bristol-Myers Squibb Company on 03/26/2021
Selinexor + Dexamethasone Submitted by Karyopharm Therapeutics on 05/03/2021
Pomalidomide Submitted by Bristol-Myers Squibb Company on 07/07/2021
Lenalidomide Submitted by Bristol-Myers Squibb Company on 07/15/2021
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 07/19/2021
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 08/26/2021
elotuzumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Selinexor_carfilzomib_dexamethasone Submitted by Karyopharm Therapeutics on 11/23/2021
Gene expression profiling Submitted by SkylineDX on 03/30/2022
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 11/22/2022
Talquetamab Submitted by Janssen Scientific Affairs, LLC on 06/19/2023
Daratumumab in combination with Lenalidomide Submitted by Janssen Scientific Affairs on 12/12/2023
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 12/21/2023
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 12/21/2023
Ibrutinib + Rituximab Submitted by AbbVie Inc. on 01/24/2024
Isatuximab/Carfilzomib/Lenalidomide/Dexamethasone Submitted by Amgen on 02/12/2024
Ixazomib plus lenalidomide and dexamethasone Submitted by Takeda Oncology on 03/04/2024
Ciltacabtagene autoleucel Submitted by Janssen Scientific Affairs on 04/08/2024
Bortezomib and Dexamethasone Submitted by Sanofi on 06/05/2024
Myelodysplastic Syndromes Panel
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 01/09/2020
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 04/10/2020
Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 03/12/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 04/01/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 12/13/2021
luspatercept Submitted by Bristol-Myers Squibb Company on 12/13/2022
luspatercept Submitted by Bristol-Myers Squibb Company on 06/12/2023
luspatercept Submitted by Bristol-Myers Squibb Company on 08/29/2023
luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 09/09/2023
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 10/25/2023
Myeloproliferative Neoplasms Panel
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 07/16/2020
Ropeginterferon alfa-2b-njft Submitted by PharmaEssentia Corporation on 07/14/2022
Pemigatinib (MLNE) Submitted by Incyte Corporation on 08/01/2022
Cetirizine/IV Oral Antihistamines Submitted by TerSera Therapeutics on 03/06/2023
IV cetirizine Submitted by TerSera Therapeutics on 06/06/2023
Ropeginterferon alfa-2b-njft Submitted by PharmaEssentia Corporation on 07/18/2023
Liver-Directed Therapy Submitted by Society of Interventional Oncology on 10/15/2019
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2020
TMB and pembrolizumab Submitted by Foundation Medicine, Inc. on 09/18/2020
Liver Directed Therapy Submitted by Society of Interventional Oncology on 10/08/2020
Principles of Hormone Control Submitted by TerSera Therapeutics on 10/27/2020
PRRT Lu DOTATATE Submitted by Novartis Pharmaceuticals Corporation on 09/22/2021
Telotristat ethyl Submitted by TerSera Therapeutics on 10/28/2021
Letetium Lu dotatate Submitted by Novartis Pharmaceuticals Corporation on 01/18/2022
lanreotide injection Submitted by Ipsen Biopharmaceuticals, Inc. on 03/11/2022
lanreotide Submitted by Ipsen Biopharmaceuticals, Inc. on 03/11/2022
nivolumab in combination with ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Tecentriq in combination with Avastin Submitted by Genentech, Inc. on 09/07/2022
Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel
Ramucirumab Submitted by Eli Lilly and Company on 10/29/2019
Selpercatinib Submitted by Eli Lilly and Company on 03/27/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 05/06/2020
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/15/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/26/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/29/2020
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 08/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/18/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/21/2021
Integrated Classifier Submitted by Medical University of South Carolina on 01/27/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/10/2021
Albumin-bound paclitaxel Submitted by Bristol-Myers Squibb Company on 05/14/2021
Amivantamab-vmjw Submitted by Janssen Biotech, Inc. on 05/24/2021
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
Genetics Submitted by Myriad Genetic Laboratories, Inc. on 06/16/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/17/2021
IGTA Submitted by Society of Interventional Oncology on 06/18/2021
Neoadjuvant Therapy Submitted by Champalimaud Foundation on 02/16/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 03/04/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/16/2022
Pembrolizumab + Ramucirumab Submitted by Merck & Co., Inc. on 06/03/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/08/2022
Nivolumab + Ipilimumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 06/08/2022
Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/09/2022
Comprehensive Genomic Profiling Submitted by Guardant Health on 06/16/2022
Broad Molecular Profiling Submitted by Eli Lilly and Company on 06/17/2022
Amivantamab-vmjw Submitted by Janssen Scientific Affairs, LLC on 07/05/2022
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 08/12/2022
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 08/22/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/07/2022
Adagrasib Submitted by Mirati Therapeutics, Inc. on 10/31/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 11/08/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 11/11/2022
Nivolumab + Ipilimumab + Chemotherapy Submitted by Genentech, Inc. on 11/11/2022
Durvalumab + Tremelimumab-actl Submitted by AstraZeneca on 11/14/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 05/05/2023
Comprehensive Genomic Profiling Submitted by Guardant Health on 05/31/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 06/03/2023
Encorafenib + Binimetinib Submitted by Pfizer Inc. on 06/05/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 06/07/2023
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/09/2023
Image-guided thermal ablation Submitted by Society of Interventional Oncology on 06/09/2023
Nivolumab + Ipilimumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 06/09/2023
Amivantamab-vmjw Submitted by Janssen Scientific Affairs, LLC on 06/12/2023
Image-guided thermal ablation Submitted by Society of Interventional Radiology on 06/12/2023
Radiation Submitted by American Society for Radiation Oncology on 06/12/2023
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 06/12/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 06/16/2023
Encorafenib + Binimetinib Submitted by Pfizer Inc. on 10/13/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 10/17/2023
Pembrolizumab + Chemotherapy Submitted by Merck & Co., Inc. on 10/24/2023
Amivantamab-vmjw and Carboplatin-Pemetrexed Submitted by Janssen on 11/06/2023
Osimertinib plus platinum-pemetrexed Submitted by AstraZeneca on 11/12/2023
Amivantamab-vmjw and Carboplatin-Pemetrexed Submitted by Janssen on 11/21/2023
Amivantamab-vmjw and lazertinib Submitted by Johnson & Johnson on 06/27/2024
Durvalumab Submitted by AstraZeneca Pharmaceuticals LP and AstraZeneca on 08/15/2024
Amivantamab-vmjw Submitted by Johnson & Johnson on 08/20/2024
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024
Pembrolizumab with Pemetrexed and Platinum Chemotherapy Submitted by Merck & Co., Inc. on 09/19/2024
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Evaluation and management Submitted by Foundation Medicine, Inc. on 03/22/2022
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Erdafitinib Submitted by Janssen Scientific Affairs on 11/15/2023
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/11/2020
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 03/05/2021
IV Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 10/05/2021
IV Cetirizine Submitted by TerSera Therapeutics on 09/14/2022
IV Cetirizine Submitted by TerSera Therapeutics on 06/14/2023
Trabectedin Submitted by Janssen Scientific Affairs, LLC on 02/04/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2020
myChoice CDx Submitted by Myriad Genetic Laboratories, Inc. on 09/08/2020
OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 09/16/2020
CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020
Selinexor Submitted by Karyopharm Therapeutics on 01/21/2021
Niraparib + Bevacizumab Submitted by GlaxoSmithKline on 03/22/2021
Surveillance Submitted by Sunnybrook Health Sciences Centre on 04/08/2021
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/01/2021
Comprehensive Molecular Testing Submitted by Foundation Medicine, Inc. on 09/09/2021
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 10/07/2021
Nivolumab + ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Niraparib + bevacizumab Submitted by GlaxoSmithKline on 06/14/2022
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/16/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/29/2022
Mirvetuximab soravtansine Submitted by ImmunoGen, Inc. on 10/03/2022
Mirvetuximab soravtansine + bevacizumab Submitted by ImmunoGen, Inc. on 10/03/2022
Olaparib (+/- bevacizumab) Submitted by AstraZeneca on 10/14/2022
VENTANA FOLR1 RxDx Assay Submitted by Roche Diagnostic Corporation on 02/06/2023
Platinum refractory. Submitted by AdventHealth Cancer Institute on 03/06/2023
Niraparib + bevacizumab Submitted by GlaxoSmithKline on 04/17/2023
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/05/2023
Oncokb Submitted by Memorial Sloan Kettering Cancer Center on 06/22/2023
Cetirizine hydrochloride for injection Submitted by TerSera Therapeutics on 06/30/2023
Goserelin implant Submitted by TerSera Therapeutics on 07/28/2023
IP carboplatin Submitted by Saitama Medical University International Medical Center on 08/10/2023
Adagrasib Submitted by Mirati Therapeutics, Inc. on 08/11/2023
Olaparib Submitted by Myriad Genetic Laboratories, Inc. on 08/28/2023
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 09/01/2023
Mirvetuximab soravtansine-gynx + bevacizumab Submitted by ImmunoGen, Inc. on 09/01/2023
Pancreatic Adenocarcinoma Panel
Evidence Blocks Submitted by United Healthcare on 02/24/2020
Germline testing Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020
Multi-gene panel testing Submitted by Myriad Genetic Laboratories, Inc. on 05/20/2021
Methylation-based blood test Submitted by Grail, Inc. on 06/21/2021
nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO link Submitted by American Society for Radiation Oncology on 04/26/2022
selpercatinib Submitted by Eli Lilly and Company on 07/01/2022
Pembrolizumab Submitted by Foundation Medicine, Inc. on 07/13/2022
Locoregional therapies Submitted by Society of Interventional Oncology on 07/14/2022
selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
NALIRIFOX Submitted by Ipsen Biopharmaceuticals, Inc. on 01/20/2023
Oncogenic Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
liposomal irinotecan Submitted by Ipsen Biopharmaceuticals, Inc. on 09/12/2023
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Fam-Trastuzumab Deruxtecan-nxki Submitted by Daiichi Sankyo, Inc. and AstraZeneca on 04/08/2024
Pediatric Acute Lymphoblastic Leukemia Panel
ClonoSEQ® Assay Submitted by Adaptive Biotechnologies on 05/22/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 10/26/2020
MRD Testing Submitted by Adaptive Biotechnologies on 05/19/2021
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
asparaginase erwinia chrysanthemi Submitted by Jazz Pharmaceuticals Inc. on 04/08/2022
glucarpidase and MTXPK tool Submitted by BTG International on 05/19/2022
IV Cetirizine Submitted by TerSera Therapeutics on 03/22/2023
Pediatric Aggressive Mature B-Cell Lymphomas Panel
Pediatric Central Nervous System Cancers Panel
Pediatric Hodgkin Lymphoma Panel
Prevention and Treatment of Cancer-Related Infections Panel
Prostate Cancer Early Detection Panel
Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020
miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020
ExactVu 29MHz Micro-Ultrasound system Submitted by Exact Imaging Inc. on 11/10/2020
IsoPSA Submitted by Cleveland Diagnostics, Inc. on 09/15/2021
Stockholm3 Submitted by Karolinska Institutet and A3P Biomedical AB on 09/19/2021
miR Scientific Sentinel Submitted by Vanderbilt University Medical Center on 09/20/2021
miR Scientific Sentinel_2 Submitted by Vanderbilt University Medical Center on 09/20/2021
Stockholm3 Submitted by Karolinska Institutet and A3P Biomedical AB on 08/18/2023
Molecular/Biomarker Analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 04/29/2020
Laser Focal Therapy Submitted by Halo Diagnostics on 06/06/2020
apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/25/2021
Germline Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Molecular Marker Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/14/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Decipher Submitted by Decipher Biosciences Inc. on 04/16/2021
fluciclovine Submitted by Blue Earth Diagnostics on 05/06/2021
piflufolastat F 18 Submitted by Lantheus Holdings on 06/28/2021
olaparib plus abiraterone Submitted by AstraZeneca on 02/17/2022
Pluvicto Submitted by Novartis Pharmaceuticals Corporation on 03/23/2022
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/01/2022
molecular and biomarker analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/08/2022
nivolumab ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
olaparib plus abiraterone Submitted by AstraZeneca on 06/03/2022
ArteraAI Prostate Test Submitted by Artera, Inc on 06/12/2022
Cabozantinib with atezolizumab Submitted by Exelixis Inc. on 07/22/2022
BRCA testing for high-risk prostate cancer Submitted by Linda W. Wilson M.D. INC on 09/29/2022
Relugolix Submitted by Myovant Sciences, Inc. and Pfizer Inc. on 04/18/2023
Molecular Marker Submitted by Myriad Genetic Laboratories, Inc. on 04/20/2023
Ablation Types Submitted by Society of Interventional Radiology on 04/20/2023
Comprehensive Genomic Profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/21/2023
flotufolastat F 18 Submitted by Blue Earth Diagnostics on 05/30/2023
Olaparib/abiraterone for mCRPC and BRCAm Submitted by AstraZeneca on 06/01/2023
talazoparib/enzalutamide for adult patients with HRRm mCRPC Submitted by Pfizer Inc. on 06/26/2023
Niraparib/abiraterone Submitted by Janssen Scientific Affairs, LLC on 08/14/2023
EMBARK Submitted by Astellas Pharma Inc. and Pfizer Inc. on 12/08/2023
Skin Cancers Excluding Melanoma Panel
Pembrolizumab for Basal Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Merkel Cell Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 03/26/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021
Sonidegib Submitted by Sunesis Pharmaceuticals, Inc. on 02/26/2021
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 07/13/2021
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/29/2022
40-GEP Submitted by University of Rochester Medical Center, Department of Dermatology on 04/19/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 10/03/2022
IGRT for Squamous Cell Skin Cancer Submitted by eviCore Healthcare on 01/03/2023
Avelumab for Merkel Cell Carcinoma Submitted by EMD Serono on 02/03/2023
Nivolumab for Merkel Cell Carcinoma Submitted by Bristol-Myers Squibb Company on 02/14/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 03/23/2023
GEP tests for Squamous Cell Skin Cancer Submitted by Castle Biosciences on 04/03/2023
40-GEP test for Squamous Cell Skin Cancer Submitted by Castle Biosciences on 04/27/2023
40-GEP for Squamous Cell Skin Cancer Submitted by SkinCure Oncology on 05/01/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
Retifanlimab-dlwr Submitted by Incyte Corporation on 11/06/2023
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/04/2019
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 04/29/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 06/15/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/04/2022
Treatment Algorithm Submitted by The Desmoid Tumor Research Foundation on 03/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 05/18/2020
Footnotes Submitted by Society of Interventional Oncology on 06/08/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 08/17/2020
Selinexor Submitted by Karyopharm Therapeutics on 04/11/2022
Atezolizumab for ASPS Submitted by Genentech, Inc. on 06/15/2022
Request hepatic artery embolization Submitted by Society of Interventional Oncology on 08/11/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Pembrolizumab MSI-H or dMMR Submitted by Merck & Co., Inc. on 03/30/2023
Pembrolizumab MSI-H or dMMR Submitted by Merck & Co., Inc. on 03/30/2023
Oncogenic OncoKB Submitted by Memorial Sloan Kettering Cancer Center on 06/23/2023
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/24/2023
Eribulin in combination with gemcitabine Submitted by Eisai Inc. on 08/28/2023
Nirogacestat Submitted by Springworks Therapeutics on 11/27/2023
Nirogacestat Submitted by Springworks Therapeutics on 11/27/2023
Atezolizumab and Hyaluronidase-tqjs Submitted by Genentech on 09/12/2024
Genetic risk assessment and testing Submitted by Myriad Genetic Laboratories, Inc. on 10/29/2019
Head and neck lymphedema Submitted by Vanderbilt University School of Nursing on 11/09/2020
Web-based Survivorship Care Plan Submitted by OncoLink on 08/04/2021
Zoster Vaccine Recombinant, Adjuvanted [RZV]) Submitted by GlaxoSmithKline on 10/23/2021
Lymphedema management Submitted by Yale New Haven Health - Greenwich Hospital on 09/23/2022
Predictive diagnostic assay Submitted by Biotheranostics on 08/28/2023
T-Cell/Primary Cutaneous Lymphomas Panel
Leucovorin Submitted by Acrotech Biopharma LLC on 06/12/2020
ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies on 06/19/2020
Romidepsin Submitted by Bristol-Myers Squibb Company on 12/03/2021
Mechlorethamine gel Submitted by Helsinn Therapeutics, Inc. on 12/09/2022
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024
Denileukin diftitox-cxdl Submitted by Citius Pharma on 07/01/2024
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020
Lenvatinib and pembrolizumab Submitted by Eisai Inc. on 09/24/2021
Diagnostic Procedures Submitted by Myriad Genetic Laboratories, Inc. on 09/24/2021
Molecular Diagnostics Submitted by Veracyte, Inc. on 10/06/2021
Oncogenic mutations in RET Submitted by Memorial Sloan Kettering Cancer Center on 05/30/2023
Personal and family history screening Submitted by Myriad Genetic Laboratories, Inc. on 07/31/2023
Selpercatinib Submitted by Eli Lilly and Company on 10/23/2023
No portion of this Site or any NCCN Content may be copied, transferred, reproduced, modified, or otherwise used for any purpose without NCCN’s express written permission.
See Legal Notices Section for additional notices and terms governing your use of this Site.